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Abstract
Human aquaporin 4 (AQP4) is the primary water channel protein in brain astrocytes. Hypothermia is known to cause astrocyte
swelling in culture, but the precise role of AQP4 in this process is unknown. Primary human cortical astrocytes were cultured
under hypothermic (32 °C) or normothermic (37 °C) conditions. AQP4 transcript, total protein and surface-localized protein were
quantified using RT-qPCR, sandwich ELISA with whole cell lysates or cell surface biotinylation, followed by ELISA analysis of the
surface-localized protein, respectively. Four-hour mild hypothermic treatment increased the surface localization of AQP4 in human
astrocytes to 155  4% of normothermic controls, despite no change in total protein expression levels. The hypothermia-
mediated increase in AQP4 surface abundance on human astrocytes was blocked using either calmodulin antagonist (trifluoper-
azine, TFP); TRPV4 antagonist, HC-067047 or calcium chelation using EGTA-AM. The TRPV4 agonist (GSK1016790A) mimicked
the effect of hypothermia compared with untreated normothermic astrocytes. Hypothermia led to an increase in surface localiza-
tion of AQP4 in human astrocytes through a mechanism likely dependent on the TRPV4 calcium channel and calmodulin activa-
tion. Understanding the effects of hypothermia on astrocytic AQP4 cell surface expression may help develop new treatments for
brain swelling based on an in-depth mechanistic understanding of AQP4 translocation.
Introduction
Hypothermia is known to have speciﬁc effects on the blood–brain bar-
rier (BBB), including changes in blood ﬂow, metabolism, water home-
ostasis and excitotoxicity, as well as signalling proﬁles leading to
changes in apoptosis and cell survival (Yenari & Han, 2012).
Hypothermia was reported to be neuroprotective in stroke patients
(Yenari & Hemmen, 2010), but in traumatic brain injury (TBI), a ther-
apeutic role for hypothermia is controversial; different clinical trials
have reported both positive and negative outcomes on patient recovery
(Andrews et al., 2015; Lazaridis & Robertson, 2016). Cytotoxic
oedema, which is a feature of stroke and TBI, occurs when water
enters the CNS via astrocytes at the BBB, predominantly through the
aquaporin 4 (AQP4) channel, and knockout of AQP4 is protective
against cytotoxic oedema development in various animal models
(Verkman et al., 2006). The speciﬁc effects of hypothermia on AQP4
expression in human astrocytes are not known. AQP4 expression in
rat astrocytes has been reported to increase after 2 h in response to
transarterial (cold saline) hypothermia infusion in a middle cerebral
artery occlusion (MCAO) model (Kurisu et al., 2016). In a rat model
of thrombin-induced vasogenic oedema, AQP4 protein levels
increased after 24 h, peaking at 48 h (Gao et al., 2015). Conversely,
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hypothermia-induced reduction in cytotoxic cerebral oedema, in a por-
cine model of cardiac arrest/resuscitation, was concomitant with a
reduction in AQP4 protein levels after 24 h (Zhao et al., 2012). Addi-
tionally, mild hypothermia was reported to cause a signiﬁcant astro-
cyte volume increase to 107.3  0.4% (mean  SEM) of control,
after 30 min at 32 °C (Plesnila et al., 2000).
Many factors have been reported to alter AQP4 abundance and
subcellular localization, including vasopressin, histamine and astro-
cytic glutamate (Conner et al., 2013). We recently described a
mechanism of short-term AQP4 relocalization during tonicity-driven
cell swelling in rat astrocytes (Kitchen et al., 2015). To our knowl-
edge, hypothermia has not been previously investigated as a trigger
of AQP4 relocalization.
In addition to AQP4, the stretch-activated transient receptor
potential vanilloid 4 calcium channel (TRPV4) is known to be
essential in cell volume regulation: a TRPV4-mediated increase in
Ca2+ inﬂux has been suggested to have an effect on the AQP-
mediated cell volume regulation following osmotic stress and the
activity and localization of TRPV4 was often dependent on aqua-
porin expression (Benfenati et al., 2011). They proposed that a
TRPV4/AQP4 complex at the astrocyte membrane was an essential
component of an osmosensory system that couples osmotic stress to
downstream signalling pathways (Benfenati et al., 2011).
This study demonstrates that mild hypothermia, as used therapeu-
tically (32 °C), can increase the localization of endogenous AQP4
to the plasma membrane of human primary cortical astrocytes and
that this process can be disrupted by inhibition of TRPV4 or
calmodulin and by chelation of intracellular calcium. Given the
well-established permissive role of AQP4 in cytotoxic oedema
development, our data may help to explain why hypothermic inter-
vention in conditions involving cytotoxic oedema is sometimes dele-
terious and suggest novel hypothermic/pharmacological combination
therapies for cytotoxic oedema.
Materials and methods
Cell culture
Primary human cortical astrocytes (ScienCell) were used following
the manufacturer’s protocol. All cells were used at passage 4 or
below. The cells were incubated in humidiﬁed 5% (v/v) CO2 in air
at 37 °C or 32 °C.
RT-qPCR
Total RNA was isolated using a Qiagen RNeasy Plus Mini Kit (Qia-
gen), according to the manufacturer’s instructions, and multi-target
RT-qPCR was performed using a StepOnePlusTM Real-Time PCR Sys-
tem (Applied Biosystems) with puriﬁed cDNA samples generated
using SuperScriptTM III Reverse Transcriptase (Thermo Fisher Scien-
tiﬁc) and QIAquick PCR Puriﬁcation Kit (Qiagen) to investigate gene
expression levels of AQP4 mRNA using Taqman primers (Thermo
Fisher; ID: Hs00242342_m1). PPIA (assay ID: Hs99999904_m1) and
CDKN1B (assay ID: Hs00153277_m1; Applied Biosystems) were
used as control housekeeping genes. Results were analysed using the
2DDCt method and presented as relative gene expression normalized
to the average cycle threshold for the two housekeeping genes.
ELISA
AQP4 and calmodulin protein levels were measured by sandwich
ELISA following the manufacturer’s instructions (Abcam) and as
described by Salman et al. (2017), using rabbit polyclonal anti-AQP4
antibody (Abcam, ab46182) and mouse monoclonal anti-AQP4 anti-
body (Abcam, ab9512) or rabbit polyclonal anti-calmodulin antibody
(Abcam, ab38590) with mouse monoclonal anti-calmodulin antibody
(Abcam, ab2860). The secondary antibody used in both assays was
chicken anti-mouse IgG-HRP antibody (Santa Cruz, sc-2954).
Cell surface biotinylation (CSB)
This was performed as described by Kitchen et al. (2015). Brieﬂy,
cell surface proteins were biotinylated using a cell-impermeable
amine-reactive biotinylation reagent (EZ-Link Sulfo-NHS-SS-Biotin;
Thermo Cat. No. 21331). 96-well PierceTM NeutrAvidinTM coated
plates (Thermo Scientiﬁc; Cat. No. 15129) were used to pull down
the biotinylated proteins within the total cell lysate. After washing
off unbound proteins, the plate was then incubated with anti-AQP4
antibody (Abcam, ab128906) diluted 1 : 500 in 0.05% PBS-tween
(PBS-T), which bound to the cell surface biotinylated AQP4 pro-
teins attached to the avidin coated plate. Anti-AQP4 antibody vali-
dation data are provided in Fig. S1.
Cell treatments
Hypotonic challenges were achieved by dilution of media with
dH2O to 85 mOsm/kg H2O; osmolality was measured using an
Osmomat 3000 freezing point depression osmometer (Gonotec).
Inhibitors were used at 1009 published IC50 values and were added
30 min prior to initiation and maintained for the duration of each
experimental setting. TRPV4 inhibitor (HC-067047) was used at a
concentration of 4.8 lM, while calmodulin antagonist (triﬂuoper-
azine, TFP) was used at a concentration of 127 lM. The potent
TRPV4 channel agonist GSK1016790A (Sigma) was used at a con-
centration of 2.1 lM; it was added either 30 min before the interven-
tion or at the same time as the intervention. Intracellular calcium
chelation was performed using EGTA AM (Invitrogen; E1219) at a
concentration of 5 lM following the manufacturer’s recommenda-
tion. In all cases, cells were at least 92% viable, assessed using
CellTiter-Glo Luminescent Cell Viability Assay.
Statistical analysis
All data are presented as a fold change normalized to the experi-
mental control. RT-qPCR expression, ELISA and cell surface
biotinylation data were found to be nonparametric in distribution
using the Shapiro–Wilk test. A Kruskal–Wallis analysis with a
Conover–Inman post hoc test was therefore used to identify signiﬁ-
cant differences (P ≤ 0.05) using STATSDIRECT 3 software. Addition-
ally, data have been reproduced as box-and-whisker plots and are
provided collectively in Fig. S2.
Results
RT-qPCR and ELISA of AQP4 following hypothermia in
primary human astrocytes
There was a modest increase in AQP4 mRNA levels in cultured
human primary astrocytes (measured using RT-qPCR) following 4 h
mild hypothermia (32 °C) compared with control cells grown at
37 °C (Fig. 1A): the increase was 156%  16%; P = 0.035 (n = 4).
However, Fig. 1B shows that this small increase in transcript abun-
dance was not translated into a change in protein levels (measured
by ELISA), which were not signiﬁcantly different (P > 0.05).
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AQP4 plasma membrane abundance using cell surface
biotinylation following hypothermia in primary human
astrocytes
Cell surface AQP4 expression after 4 h mild hypothermia (32 °C)
was compared to cells at 37 °C using an AQP4 biotinylation assay
[as described in our previous study (Kitchen et al., 2015)]. The
results show that despite there being no change in total AQP4 protein
levels (Fig. 1B), AQP4 levels at the cell surface increased to
155  4% (P < 0.0001) of control values following hypothermia
(Fig. 2); the modest decrease in surface localization of the control
membrane protein, amino acid transporter EAAT1, indicates that the
hypothermia-induced increase in AQP4 plasma membrane localiza-
tion is not a global response to hypothermia associated with all
membrane proteins.
Hypotonicity is known to cause cellular swelling and increase in
AQP4 surface localization and was used a positive control. Figure 2
shows that hypotonicity signiﬁcantly increases the AQP4 levels at
the cell surface to 192  11% (P < 0.0001) of control values with
no signiﬁcant difference in EAAT1 levels (P = 0.579).
Validation of calmodulin- and TRPV4-dependent mechanism
in AQP4 translocation following hypothermia in primary human
astrocytes
We previously identiﬁed a regulatory mechanism for AQP4 surface
localization in an in vitro model using rat astrocyte cell swelling in
response to reduced extracellular osmolality (Kitchen et al., 2015).
Calmodulin was a key regulator of this process, and extracellular
Ca2+ was essential to mediate the translocation. We therefore mea-
sured the localization of AQP4 following inhibition of either calmod-
ulin (using TFP); TRPV4 (using HC-067047) or calcium (using
EGTA-AM); Fig. 3 shows that all the investigated inhibitors blocked
relocalization of AQP4 in human primary astrocytes following 32 °C
hypothermia. We have previously shown no effect of either TFP or
removal of extracellular calcium on the initial (i.e. pre-swelling-
induced relocalization) distribution of AQP4 in rat astrocytes
(Kitchen et al., 2015) suggesting TRPV4 and calmodulin inhibition
are disrupting this hypothermic relocalization phenomenon.
The data in Fig. 3 indicated that calmodulin activation is required
for AQP4 relocalization. Therefore, we assessed calmodulin protein
levels under the same hypothermic conditions. Our data showed that
4 h mild hypothermia (32 °C) signiﬁcantly increased calmodulin
expression to 158  5% (P < 0.0001) compared with cells grown
at 37 °C (n = 4).
The involvement of TRPV4 was investigated further using the
TRPV4 agonist, GSK1016790A. Figure 4 shows that treating astro-
cytes with GSK1016790A causes a signiﬁcant increase in AQP4
surface expression, 145  10% (P = 0.0042) compared to control
levels, similar to what was observed after hypothermia. Interestingly,
there was no additive effect of TRPV4 agonist and hypothermia.
Agonist was added 30 min before hypothermia in order to follow
the same experimental protocol used for the antagonists. We specu-
lated that this ‘pre-treatment’ may have caused internalization of
TRPV4 (which has been reported for GSK1016790A; Shibasaki
et al., 2015), leading to the absence of TRPV4 at the surface for
activation by hypothermia. To test this, we repeated the experiment
Fig. 1. AQP4 mRNA and protein expression levels in cultured primary human astrocytes. Data are mean fold changes in expression (SEM) of cells incubated
at 32 °C for 4 h (labelled ‘Hypothermia’) compared with normothermic (‘Control’) astrocytes. Each bar represents the mean  SEM for each of the conditions.
Kruskal–Wallis with Conover–Inman post hoc analysis tests were used to identify signiﬁcant differences between samples. *Represents statistical signiﬁcance
(P < 0.05). Panel (A) shows RT-qPCR data (N = 5) using Taqman probes and 2DDCt analysis normalized to the two housekeeping genes, PPIA and CDKN1B.
Panel (B) shows sandwich ELISA data (N = 4).
Fig. 2. AQP4 cell surface localization in primary human astrocytes. Data
are mean fold changes in expression (SEM) of cells incubated at 32 °C for
4 h (Hypothermia) or 85 mOsm/kg H2O (Hypotonicity) compared with
normothermic (Control) astrocytes. Each bar represents the mean  SEM for
each of the conditions. Kruskal–Wallis with Conover–Inman post hoc analy-
sis tests were used to identify signiﬁcant differences between samples
(n = 4). *, ***Represents statistical signiﬁcance (*P < 0.05 and
***P < 0.001) using STATSDIRECT 3 software.
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applying the TRPV4 agonist and hypothermia simultaneously. In
this case, an additive effect of TRPV4 agonism and hypothermia
was seen, with AQP4 surface expression increasing to 183  4%
(P = 0.0003) of control, signiﬁcantly higher than either TRPV4 ago-
nist alone (P = 0.0039) or hypothermia alone (P = 0.025). The
same additive effect was observed following hypotonic intervention:
AQP4 surface expression was increased to 189  10% (P = 0.045)
with TRPV4 agonist pre-treatment and 223  5% (P = 0.0253)
with simultaneous treatment.
There were no signiﬁcant changes in EAAT1 surface expression
levels following the agonist/inhibitors in Figs 3 and 4 (data not shown).
Discussion
Hypothermia affects many physiological mechanisms of the brain
and has a widely recognized therapeutic potential in the reduction
of early-stage (cytotoxic) oedema (Previch et al., 2016). This
oedema can form when astrocytes have reduced ion homeostasis
and increased intracellular tonicity, which is followed by water
inﬂux via osmosis. This in turn is thought to activate the
mechanosensitive calcium channels (mainly TRPV4) leading to an
increase in calcium inﬂux (Benfenati et al., 2011) enhancing
calmodulin activity, including calmodulin-mediated AQP4 surface
Fig. 3. Inhibition of hypothermia-induced increase in AQP4 cell surface localization in primary human astrocytes. Data are mean fold changes in expression
(SEM) of cells incubated at 32 °C for 4 h (Hypothermia) or 85 mOsm/kg H2O (Hypotonicity) compared with normothermic (Control) astrocytes with or with-
out the indicated inhibitors. The calmodulin inhibitor is 127 lM TFP; the TRPV4 inhibitor is 4.8 lM HC-067047; the intracellular calcium chelator is 5 lM
EGTA AM. Kruskal–Wallis with Conover–Inman post hoc analysis tests were used to identify signiﬁcant differences between samples (n = 4). ***Represents
statistical signiﬁcance (***P < 0.001) using STATSDIRECT 3 software.
Fig. 4. TRPV4 channel agonist increases AQP4 cell surface localization in primary human astrocytes. Data are mean fold changes in expression (SEM) of
cells incubated at 32 °C for 4 h (Hypothermia) or 85 mOsm/kg H2O (Hypotonicity) compared with normothermic (Control) astrocytes with or without the
potent TRPV4 channel agonist (GSK1016790A) at 2.1 lM. The TRPV4 agonist was added either 30 min before the intervention (Before) or at the same time
of the intervention (Together). Kruskal–Wallis with Conover–Inman post hoc analysis tests were used to identify signiﬁcant differences between samples
(n = 4). ***Represents statistical signiﬁcance (***P < 0.001) using STATSDIRECT 3 software.
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relocalization (Verkman et al., 2014; Vella et al., 2015). The pro-
posal that hypothermia inﬂuences important cellular signalling
mechanisms is supported by recent work showing that hypothermia/
TRPV4 mediated effects on intracellular signalling (Zou et al.,
2015).
To our knowledge, this is the ﬁrst demonstration of changes to
AQP4 surface localization levels in response to hypothermic treat-
ment of human primary cortical astrocytes. We have also demon-
strated that inhibiting calmodulin (using either the antagonist, TFP
or the TRPV4 inhibitor, HC-067047) or intracellular calcium (using
EGTA-AM) blocks the hypothermia-mediated increase in AQP4
surface expression in human astrocytes. Interestingly, it has been
shown that TRPV4 activity is inhibited by cold (tempera-
ture < 34 °C) in mouse neurons (Shibasaki et al., 2015). It is also
well-established that TRPV4 opens in response to cell swelling, but
the calcium signalling responses are different in neurons (fast, inac-
tivating currents) and glia (slow currents, with sustained ½Ca2þi ele-
vation; Ryskamp et al., 2014). In astrocytes, where hypothermia
induces cell swelling, it is not obvious whether TRPV4 would be
activated by mechanical swelling, inactivated by cold, or at interme-
diate activity, depending on the exact temperature and cell volume.
Our data suggest that TRPV4 retains at least some activity in astro-
cytes at 32 °C, as the AQP4 relocalization observed in response to
hypothermia is blocked by a TRPV4 antagonist and recapitulated
by a TRPV4 agonist under normothermic (37 °C) conditions. The
absence of any additive effect between pre-treatment with TRPV4
agonist and its level at the time of hypothermic intervention could
be due to receptor internalization, which could explain the additive
effect seen when cells are exposed to the intervention and the ago-
nist at the same time.
It is thought that AQP4 deletion/knockdown is protective and
AQP4 overexpression is harmful in animal models of early brain
oedema (Verkman et al., 2006). We suggest that some of the deleteri-
ous effects of hypothermic intervention in oedema that have been
reported (Lazaridis & Robertson, 2016) may be mediated by increased
AQP4 surface expression via a TRPV4-/calmodulin-dependent relocal-
ization mechanism. Further work showing inhibition of human astro-
cytic swelling in the presence of calmodulin and/or TRPV4 inhibitors
would further support the role of AQP4 in astrocytic swelling in stoke
and traumatic injury.
Separating the mechanisms involved in the beneﬁcial and damag-
ing effects of hypothermic intervention may allow us to further reﬁne
the clinical value of hypothermia for oedema prevention following
stroke or TBI. In the future, further, co-treatment with putative AQP4
inhibitors targeting the subcellular relocalization pathway would allow
exploitation of the neuroprotective effects of hypothermia while miti-
gating any harmful effects.
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